Table Of ContentBIOGEN IDEC
2012 ANALYST DAY
JUNE 12, 2012, BIOGEN IDEC, CAMBRIDGE, MA
Primary cultures of Human Spinal Cord
Astrocytes, By SowmyaChollateand Robert
Scannevin
BIO-26791 Hydrochloride -IRAK4 project -
polarized light microscopy, By Michael MacPhee
Tree of Life, Photomicrograph
(fluorescent IHC staining). Staining of
mature oligodendrocyte,By Mi Sha
Forward-Looking Statements
This presentation contains forward-looking statements, including statements about our prospects for growth,
market share and market evolution, competitive position, regulatory filings and agency actions, commercial
launch plans, and the anticipated development, timing, data readouts and therapeutic scope of programs in our
clinical pipeline. These forward-looking statements may be accompanied by such words as “anticipate,”
“believe,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “project,” “target,” “will” and other words and
terms of similar meaning. You should not place undue reliance on these statements.
These statements involve risks and uncertainties that could cause actual results to differ materially from those
reflected in such statements, including our dependence on our three principal products, AVONEX® (interferon
beta 1a), RITUXAN® (rituximab) and TYSABRI® (natalizumab), the importance of TYSABRI’s sales growth,
uncertainty of success in commercializing other products, product competition, the occurrence of adverse safety
events with our products, changes in the availability of reimbursement for our products, adverse market and
economic conditions, our dependence on collaborations and other third parties over which we may not always
have full control, failure to comply with government regulation, our ability to protect our intellectual property
rights, and have sufficient rights to market our products and services together with the cost of doing so,
problems with our manufacturing processes and our reliance on third parties, the risks of doing business
internationally, failure to execute our growth initiatives, charges and other costs relating to our properties,
fluctuations in our effective tax rate, our ability to attract and retain qualified personnel, product liability claims,
fluctuations in our operating results, the market, interest and credit risks associated with our portfolio of
marketable securities, our level of indebtedness, environmental risks, change of control provisions in our
collaborations and the other risks and uncertainties that are described in the Risk Factors section of our most
recent annual or quarterly report and in other reports we have filed with the SEC.
These statements are based on our current beliefs and expectations and speak only as of the date of this
presentation. We do not undertake any obligation to publicly update any forward-looking statements.
2
TBIIOTGLEEN OIDFE C
PRESENTATION
2012 ANALYST DAY
GEORGE SCANGOS, PHD, CHIEF EXECUTIVE OFFICER JUNE 12, 2012
Biogen Idec 2012 Analyst Day
AGENDA
Welcoming Comments
George Scangos, PHD, Chief Executive Officer 10:00 –10:10AM
Commercial Strategy: 2012 & Beyond
Tony Kingsley, EVP Global Commercial Operations 10:10 –10:40AM
R&D Revitalization
Doug Williams, PHD, EVP, Research & Development 10:40 –11:10AM
Late Stage Pipeline
Al Sandrock, MD, PhD, SVP
Development Sciences & Chief Medical Officer 11:10 –11:40AM
(cid:190) BG-12, TYSABRI, Dexpramipexole
Glenn Pierce, MD, PhD, SVP
Global Medical Affairs and Hemophilia 11:40 –12:10PM
(cid:190) Factor 8, Factor 9
Lunch and Q&A 12:10 –12:45PM
Early Stage Pipeline
Theresa Podrebarac, MD, MSc, VP, Medical Research 12:45 –1:15PM
(cid:190) TWEAK, Syk, STX 100
Al Sandrock, MD, PhD, SVP
Development Sciences & Chief Medical Officer 1:15 –1:45PM
(cid:190) LINGO, Neublastin, SMA
Panel Q&A 1:45 –2:15PM
4
Biogen Idec 2012 Analyst Day
GEORGE SCANGOS, PHD
CHIEF EXECUTIVE OFFICER (SPEAKER)
George A. Scangos, Ph.D., is our Chief Executive Officer and a member of the Board of
Directors of Biogen Idec and has served in these positions since June 2010. He joined
the company from Exelixis, Inc., where he served as President and CEO and a director
since October 1996. From September 1993 to October 1996, Dr. Scangos served as
President of Bayer Biotechnology, where he was responsible for research and
development, business development, process development, manufacturing, engineering
and quality assurance of Bayer’s biological products. Before joining Bayer in 1987, Dr.
ScangoswasaProfessorofBiologyatJohnsHopkinsUniversity.Heisalsoamemberof
the Board of Visitors of the University of California, San Francisco School of Pharmacy,
and the National Board of Visitors of the University of California, Davis School of
Medicine.HeiscurrentlyanAdjunctProfessorofBiologyatJohnsHopkins.Dr.Scangos
holds a B.A. in Biology from Cornell University, a Ph.D. in Microbiology from the
University of Massachusetts, and was a Jane Coffin Childs Post-Doctoral Fellow at Yale
University.
DOUGLAS E. WILLIAMS, PHD
EVP, RESEARCH & DEVELOPMENT (SPEAKER)
DouglasE.Williams,Ph.D.,isourExecutiveVicePresident, Researchand Development
and has served in this position since January 2011. He joined Biogen Idec from
ZymoGenetics Inc., where he was most recently CEO and member of the Board of
Directors. Previously, he held leadership positions within the biotechnology industry,
including Chief Scientific Officer and Executive Vice President of Research and
Development at Seattle Genetics Inc., and Senior Vice President and Washington Site
Leader at Amgen Inc. Dr. Williams also served in a series of scientific and senior
leadershippositionsoveradecadeatImmunexCorp.,includingExecutiveVicePresident
and Chief Technology Officer, Senior Vice President of Discovery Research and Vice
President of Research and Development. Prior to joining Immunex, Dr. Williams served
on the faculty of the Indiana University School of Medicine and the Department of
LaboratoryMedicineattheRoswellParkMemorialInstituteinBuffalo,NewYork.
TONY KINGSLEY, EVP
GLOBALCOMMERCIALOPERATIONS(SPEAKER)
TonyKingsleyisourExecutiveVicePresidentofGlobalCommercialOperationsandhas
served in this position since November 2011. Mr. Kingsley also served as Senior Vice
President of U.S. Commercial Operations. Prior to joining Biogen Idec in January 2010,
Mr. Kingsley was Senior Vice President and General Manager of the Gynecological
Surgical Products business at Hologic, Inc., where he ran Sales & Marketing, R&D and
Operations. He also served as Division President, Diagnostic Products for Cytyc Corp.,
where he directed U.S. commercial operations and had global responsibility for
manufacturing and supply chain, field and technical service, regulatory and quality, and
R&D. From 1991-2006, Mr. Kingsley was a Partner at McKinsey and Company, Inc.,
focusing on the pharmaceuticals, biotech and medical device industries. Mr. Kingsley
holdsaB.A.degreeinGovernmentfromDartmouthCollegeandanM.B.A.fromHarvard
GraduateSchoolofBusinessAdministration.
Biogen Idec 2012 Analyst Day
ALFRED W. SANDROCK, MD, PHD
SVP, DEVELOPMENT SCIENCES & CHIEF MEDICAL OFFICER (SPEAKER)
Alfred W. Sandrock Jr., M.D., Ph.D., is Chief Medical Officer at Biogen Idec, overseeing
clinical development in neurological and immunological indications, regulatory affairs,
safety and benefit risk assessment, biometrics, and global clinical development
operations. Dr. Sandrock is a board-certified neurologist and is Assistant Clinical
Professor of Neurology at Harvard Medical School. His contributions to the literature
include peer-reviewed articles on axonal regeneration, synapse formation,
neurophysiology, and multiple sclerosis. Dr. Sandrock received an MD from Harvard
Medical School in Boston, and a PhD in Neurobiology from Harvard University in
Cambridge. He completed an internship in Medicine, a residency and chief residency in
Neurology, and a Clinical Fellowship in Neuromuscular Disease and Clinical
Neurophysiology(electromyography)atMassachusettsGeneralHospital.
GLENN PIERCE, MD, PHD
SVP, GLOBAL MEDICAL AFFAIRS AND HEMOPHILIA (SPEAKER)
Dr. Pierce, Biogen Idec’s SVP, Global Medical Affairs since March 2012, joined Biogen
Idec's hemophilia therapeutic area as a Vice President and Chief Medical Office in 2009.
Prior to joining Biogen Idec, Dr. Pierce was employed by Bayer Healthcare, Bayer
ScheringPharmawherehewasScientificHead,USResearchCenterandVicePresident,
AppliedResearchHematology.Hehasmorethan20yearsofexperienceinbiotechnology
research and development, from the bench to the bedside in small, large, public and
private biotech/biopharma firms, including Avigen, Selective Genetics, and Amgen. He is
the co-author of over 150 scientific papers, has more than 9 U.S. patents, and is a
member of numerous medical and scientific groups including the WFH, NHF, ISTH, and
ASH.Dr.PierceservedontheBloodProductsAdvisoryCommitteeattheFoodandDrug
Administration and served on the Medical and Scientific Advisory Council, the Board of
Directors and was President of the Board of the National Hemophilia Foundation. Dr.
Pierce also served on the Committee on Blood Safety and Availability at the Department
of Health and Human Services. Dr. Pierce received an M.D. and a Ph.D. in Experimental
Pathology, both from Case Western Reserve University in Cleveland, Ohio and did his
postgraduatetrainingatWashingtonUniversityinSt.Louis.
SPYROS ARTAVANIS-TSAKONAS, PHD
CHIEF SCIENTIFIC OFFICER
Spyros Artavanis-Tsakonas, Ph.D., is our Chief Scientific Officer for R&D, joining Biogen
Idec in March 2012. He was most recently Professor of Cell Biology, Department of Cell
Biology,andDirectoroftheDevelopmentalandRegenerativeBiologyProgramatHarvard
MedicalSchool. Prior, Spyros wasProfessor, CollègedeFrance, holdingtheChair of the
Biology and Genetics of Development. Spyros' lab has been focused for many years on
the use of model organisms to define critical targets and pathways important in
development anddisease.Theidentification andelucidation of muchofthebiologyof the
NOTCH pathway traces back to Spyros' laboratory. In addition to his academic
credentials,Spyrosisthescientificco-founderofExelixis,Cellzome,andAnadys.
Biogen Idec 2012 Analyst Day
THERESA PODREBARAC, MD, MSC
VP, MEDICAL RESEARCH (SPEAKER)
Dr. Theresa Podrebarac is the Vice President of Global Immunologic Disease Clinical
Development.PriortorejoiningBiogeninthefallof2011,shewastheVicePresidentand
Global head of Rheumatology Clinical Development at EMD Serono, Inc. a division of
Merck Serono and was responsible for both early and late development projects with an
autoimmune focus and has specialized in lupus studies. Dr. Podrebarac served as
Medical Director of Clinical Development at Biogen Idec from 2001-2005 and was
involved in the Rituxan rheumatoid arthritis and Tysabri BLA filings. Dr. Podrebarac is
boardcertifiedinbothInternalMedicineandRheumatologyandhasheldappointmentsat
Harvard Medical School and Brigham and Women’s Hospital. Dr. Podrebarac received
her medical degree from the University of Western Ontario, a graduate degree in
microbiology and immunology from the University of Ottawa and completed her post-
doctoral training and graduate studies in Immunology at Harvard University. Her passion
istoinnovativelyandefficientlyadvancetargetedtherapiesinunderserveddiseases with
highmedicalneed.
TIMOTHY HARRIS, PHD, DSC
SVP,DISCOVERY SCIENCE
Tim joined Biogen Idec us from SAIC Frederick, Inc., where he was Chief Technology
Officer & Director of the Advanced Technology Program (ATP), where he provided
leadershipfortheTechnology&ResearchGroupatSAICFrederick,theprimecontractor
for the National Cancer Institute at Frederick. Tim served as the President and Chief
Executive Officer of Novasite Pharmaceuticals Inc. from January 2005 to September
2006andheservedasPresidentandChiefExecutiveOfficerforStructuralGenomiX,Inc.
(now SGX pharmaceuticals, part of Eli Lilly) for over 5 years beforehand. Dr. Harris
started his career in biotechnology in 1981 as a group leader in Molecular Biology at
CelltechGroup(nowUBCPharma)andfrom1989to1993wasDirectorofBiotechnology
at Glaxo Group Research in the U.K. From 1993 until 1999, Dr. Harris was Chief
Scientific Officer and Vice President of Research and Development at Sequana
Therapeutics Inc. in San Diego, which became Axys Pharmaceuticals, Inc. in 1998 and
was subsequently acquired by Celera Genomics. During the past five years, Dr. Harris
has served on the board of directors of Dendreon Corp. and he currently serves on the
board of directors of BG Medicine. Dr. Harris received his Ph.D. in molecular virology
fromtheUniversityofBirmingham,U.K. andwasawardedanhonorarydoctorofscience
degreefromthatUniversityin2010.
Biogen Idec 2012 Analyst Day
JO VINEY, PHD
VP, IMMUNOLOGY RESEARCH
Jo Viney joined Biogen Idec in the summer of 2011. Jo leads the Immunology Research group
whosemissionistodeveloptreatmentsforunderservedimmune-mediateddiseasesintheareasof
autoimmunity,fibrosisandtissueinjury.PriortojoiningBiogenIdec,JoheldpositionsatAmgenand
Immunex,whichshejoinedin1995. ShecompletedpostdoctoralfellowshipsatGenentechinSouth
San Francisco and at the Imperial Cancer Research Fund in London. She received her doctorate
degree from St Bartholomew's Hospital at the Universityof London.Jo isthe current President for
the Society for Mucosal Immunology (SMI), and is co-organizing the society’s next International
CongressforMucosalImmunology(ICMI2013).SheisalsoamemberoftheAmericanAssociation
of Immunologists (AAI) and the British Society for Immunology (BSI). In 2008 Jo partnered with
NaturePublishingGrouptolaunchanewjournal,MucosalImmunology,andsheremainsoneofthe
chiefeditors.SheisalsoamemberoftheScientificAdvisoryBoardforKeystoneSymposia.
TERESA COMPTON, PHD
VP, DISCOVERY SCIENCES & TRANSLATIONAL MEDICINE
Teresa Compton obtained her Bachelor of Science degree in Microbiology and Ph.D. degrees in
Cellular and Molecular Biology from the University of Tennessee. She then did postdoctoral
research at New York University Medical Center. She moved to the Scripps Research Institute for
several years prior to joining the faculty of the University of Wisconsin reaching the rank of Full
Professor in the McArdle Laboratory for Cancer Research in 2003. At UW, she held a number of
leadership positions and was continuously funded by research grants. She has published over 70
research articles. In 2005, Dr. Compton was recruited to the Novartis Institutes for Biomedical
Researchtobuildandleadagroupofscientistsfocusedonantiviraldrugdiscovery.Inthisposition,
shealsoservedastheprincipalliaisonwiththeInfectiousDiseasebusinessfranchiseandremained
active in academic endeavors such as publishing, serving on editorial boards and peer review of
funding. In 2011, Dr. Compton moved to Biogen Idec to lead a comprehensive program around
Progressive Multifocal Leukoencephalapathy (PML). In addition, Dr. Compton leads the
Translational Sciences department which encompasses systems biology technical platforms and
coreinstrumentationgroupstoenabledrugdiscoveryacrossBiogen’sportfolioandtopromoteand
designbiomarkerstrategiesforclinicaldevelopment.
PAUL CLANCY
EVP AND CHIEF FINANCIAL OFFICER
PaulJ.ClancyisourExecutiveVicePresidentandChiefFinancialOfficerandhasservedinthese
positionssince August 2007.Mr.Clancyhas alsoserved asSeniorVice PresidentofFinance and
VicePresidentofBusinessPlanningatBiogenIdec.Priortothemerger,Mr.Clancyhadservedas
VicePresidentofPortfolioManagementatBiogenInc.since2003.Hejoinedthecompanyin2001
as Vice President, US Marketing. Before joining Biogen, Mr. Clancy spent 13 years at PepsiCo,
serving in a range of financial and general management positions including most recently Vice
PresidentandGeneralManageroftheirGreatWestBusinessUnit.
TBIIOTGLEEN O IDFE C
ANALYST DAY 2012
PRESENTATION
COMMERCIAL STRATEGY: 2012 & BEYOND
TONY KINGSLEY, EXECUTIVE VICE PRESIDENT, GLOBAL COMMERCIAL OPERATIONS JUNE 12, 2012
Agenda
MS MARKET & STRATEGY OVERVIEW
Interferon franchise
TYSABRI® (natalizumab)
BG-12 (dimethyl fumarate)
HEMOPHILIA MARKET & OPPORTUNITY
6
Description:Jun 12, 2012 and quality assurance of Bayer's biological products. Prior to joining Biogen
Idec, Dr. Pierce was employed by Bayer Healthcare, Bayer.
